sr141716 has been researched along with Parkinson Disease in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Binda, KH; Brooks, DJ; Chacur, M; Landau, AM; Real, CC | 1 |
| Ambrosi, G; Antoninetti, GF; Armentero, MT; Baqi, Y; Blandini, F; Cerri, S; Franco, R; Lanciego, JL; Levandis, G; Montepeloso, E; Müller, CE; Pinna, A | 1 |
| Cassin, J; Harris, O; Kelsey, JE | 1 |
| Asbrock, N; Ferrer, B; Giuffrida, A; Kathuria, S; Piomelli, D | 1 |
| de Miguel, R; Fernández-Ruiz, J; García-Arencibia, M; González, S; Ramos, JA; Scorticati, C | 1 |
5 other study(ies) available for sr141716 and Parkinson Disease
| Article | Year |
|---|---|
Treadmill exercise modulates nigral and hippocampal cannabinoid receptor type 1 in the 6-OHDA model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Drug Inverse Agonism; Hippocampus; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Receptors, Cannabinoid; Rimonabant; Substantia Nigra | 2023 |
Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Cannabinoid Receptor Antagonists; Disease Models, Animal; Male; Neuroprotective Agents; Parkinson Disease; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Xanthines | 2014 |
The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Hypokinesia; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Pyrazoles; Rats; Rats, Long-Evans; Receptor, Cannabinoid, CB1; Rimonabant | 2009 |
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Benzazepines; Benzoxazines; Brain Chemistry; Cannabinoid Receptor Modulators; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Dyskinesias; Endocannabinoids; Gas Chromatography-Mass Spectrometry; Levodopa; Male; Morpholines; Mouth; Naphthalenes; Oxidopamine; Parkinson Disease; Piperidines; Pyrazoles; Raclopride; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Substantia Nigra; Time Factors | 2003 |
Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Autoradiography; Brain; Brain Chemistry; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Electrochemistry; gamma-Aminobutyric Acid; Gene Expression; Glutamic Acid; In Situ Hybridization; Injections, Intraventricular; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Protein Binding; Pyrazoles; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger; Rotarod Performance Test; Superoxide Dismutase; Superoxide Dismutase-1; Tyrosine 3-Monooxygenase | 2006 |